Incyte Corporation Wins FDA Approval for Jakafi XR
WILMINGTON, Del., May 1, 2026 Incyte Corporation has secured U.S. Food and Drug Administration (FDA) approval for Jakafi XR™...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
WILMINGTON, Del., May 1, 2026 Incyte Corporation has secured U.S. Food and Drug Administration (FDA) approval for Jakafi XR™...
Basel, 8 December 2025 — Roche has reported three-year follow-up findings from the pivotal phase III STARGLO study, demonstrating...
Dateline IntroductionNovember 18, 2025 — South San Francisco, CA — Rigel Pharmaceuticals has published final five-year clinical data on...
MAINZ, Germany, November 3, 2025 — BioNTech SE (Nasdaq: BNTX) reported its third quarter 2025 financial results, highlighting significant...
SAN DIEGO and TORONTO, November 3, 2025 — Aptose Biosciences Inc. (TSX: APS), a clinical-stage precision oncology company, announced...
LEHI, Utah, Oct. 23, 2025 — Halia Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on therapies targeting the root...
Princeton, N.J., September 22, 2025 – Bristol Myers Squibb (BMS) announced that its investigational cereblon E3 ligase modulator (CELMoD™)...
